Anti-vascular endothelial growth factor dosing frequency and visual outcomes in macular oedema following branch retinal vein occlusion

被引：2

作者：

Modi, Yasha S. ^{[1
]}

Goduni, Lediana ^{[1
]}

Moini, Hadi ^{[2
]}

Gibson, Andrea ^{[2
,6
]}

Boucher, Nick ^{[3
]}

Lucas, Genevieve ^{[3
]}

Dhoot, Dilsher S. ^{[4
,5
]}

机构：

[1] New York Univ Langone Hlth, New York, NY USA

[2] Regeneron Pharmaceut Inc, Tarrytown, NY USA

[3] Vestrum Hlth, Naperville, IL USA

[4] Calif Retina Consultants, Santa Barbara, CA 93103 USA

[5] Retina Consultants Amer, Santa Barbara, CA 93103 USA

[6] Ocular Therapeut, Bedford, MA USA

来源：

EYE | 2023年 / 37卷 / 16期

关键词：

INTRAVITREAL AFLIBERCEPT; CLINICAL-PRACTICE; RANIBIZUMAB;

D O I：

10.1038/s41433-023-02527-7

中图分类号：

R77 [眼科学];

学科分类号：

100212 ;

摘要：

ObjectivesTo determine the relationship between treatment frequency with intravitreal anti-vascular endothelial growth factor (anti-VEGF) agents and visual acuity (VA) outcomes in eyes with macular oedema (MO) secondary to branch retinal vein occlusion (BRVO) in US clinical practice.MethodsStudy eyes that initiated anti-VEGF injections between January 2012 and May 2016 were followed for >= 1 year in a retrospective analysis of medical records (Vestrum Health database). Eyes were analysed in 2 cohorts by treatment duration (years 1 and 2) and then in 2 subcohorts by injection frequency (<= 6 or >= 7 injections/year).ResultsAmong 3099 eyes with MO secondary to BRVO, 1197 (38.6%) received <= 6 injections (mean injections, 4.6; baseline mean VA, 53 letters) and 1902 (61.4%) received >= 7 injections through 1 year (mean injections, 8.8; baseline mean VA, 52 letters). At year 1, mean VA gain from baseline was 10.4 versus 13.9 letters in eyes receiving <= 6 versus >= 7 injections (p < 0.001). At year 2, mean VA in eyes receiving <= 6 (n = 42) versus >= 7 injections (n = 227) was 64 versus 68 letters, respectively (p = 0.19). Mean VA change between the start and end of year 2 in eyes receiving >= 7 injections in year 1 and <= 6 in year 2 differed significantly from that of eyes receiving >= 7 injections in both years (-3.0 vs 0.7 letters, respectively; p < 0.001).ConclusionsIn routine clinical practice, more frequent dosing with anti-VEGF agents was associated with greater visual benefits in eyes with MO secondary to BRVO.

引用

页码：3423 / 3428

页数：6

共 15 条

[1] Natural course of experimental retinal vein occlusion in rabbit; arterial occlusion following venous photothrombosis [J].